Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 9/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | RAB9A | P51151 | 9/20 | 0.72 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6724549 | 0.88 | RAB9A (0.80) | PKMALOX15NPC1LMNARAB9A | |
| SCHEMBL14470508 | 0.87 | PKM (0.76) | PKMALOX15NPC1LMNARAB9A | |
| SCHEMBL15975491 | 0.84 | RAB9A (1.00) | PKMALOX15NPC1LMNARAB9A | |
| SCHEMBL12196161 | 0.84 | EPHX1 (1.00) | PKMALOX15NPC1RAB9AEPHX1 | |
| SCHEMBL10210826 | 0.83 | PKM (0.71) | PKMALOX15NPC1LMNARAB9A | |
| SCHEMBL17190122 | 0.82 | RAB9A (0.72) | PKMALOX15NPC1LMNARAB9A | |
| SCHEMBL2751880 | 0.82 | RAB9A (0.97) | PKMALOX15NPC1LMNARAB9A | |
| SCHEMBL5182471 | 0.82 | PKM (0.69) | PKMALOX15NPC1LMNARAB9A | |
| SCHEMBL27308457 | 0.81 | PKM (0.68) | PKMALOX15NPC1LMNARAB9A | |
| SCHEMBL5212285 | 0.81 | PKM (0.68) | PKMALOX15NPC1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101351495-A | fatty acid amide hydrolase inhibitors | ORGANON NV (NL) | 2009-01-21 | — | — | CN | disclosed |
| EP-1969051-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. Organon (NL) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008024139-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. ORGANON (NL) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007079180-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. ORGANON (NL) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155747-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | KADMUS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155747-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ABHD6 | PKM 4262/4885ALOX15 67/4885NPC1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.